Original Article

Analysis of diarrheagenic potential of uropathogenic *Escherichia coli* isolates in Dhaka, Bangladesh

Marium Khaleque¹, Selina Akter², Humaira Akhter¹, Sirajul Islam Khan¹, Anowara Begum¹

¹Department of Microbiology, University of Dhaka, Dhaka, Bangladesh
²Department of Microbiology, Jessore University of Science and Technology, Jessore, Bangladesh

Abstract

Introduction: Uropathogenic *Escherichia coli* (UPEC) strains are chiefly responsible for urinary tract infections (UTIs). The aim of the study was to observe the virulence properties of UPEC and to determine whether they carry virulence properties of diarrheagenic *E. coli*.

Methodology: Seventy-one pure cultures were collected from UTI patients. After biochemical identification, 56 UPEC strains were examined for biofilm formation capability, hemolytic activity, presence of UTI-associated virulence genes (*papC, fim1, afa, sfa*) and diarrheaea-associated virulence genes (*estA, eltB, vt1, vt2, eaeA, aatA, bfpA*) by multiplex polymerase chain reaction (PCR) assay.

Results: Among the 56 UPEC strains, 21 showed biofilm formation ability, and only 5 showed beta-hemolytic activity. In multiplex PCR, 42% were found positive for *papC* gene, 27% were *fim1* positive, 11% were *afa* positive, and none were *sfa* positive. The diarrheagenic genes found were *vt2*, *tal*, *estA*, *eltB*, *bfpA*, and *aatA*, but only in seven isolates. Of these isolates, two were positive for *estA* and one was positive for *eltB*, characteristic genes also found in enterotoxigenic *E. coli*. One carried *vt2*, a gene characteristically found in enterohemorrhagic *E. coli*. Another one was characterized as enteropathogenic *E. coli* (EPEC), as it was carrying the EPEC gene *bfpA*. Another isolate was positive for *tal*, the characteristic gene found in enteroinvasivie *E. coli*, and one isolate was found to harbor the *aatA* gene, a gene found in all enteroaggregative *E. coli*.

Conclusions: This study revealed that most UPEC strains were unique to uropathogenic virulence properties, and very few carried diarrheagenic properties.

Key words: diarrheagenic *E. coli*; ETEC; uropathogenic *E. coli*; UTI; virulence genes.

*J Infect Dev Ctries* 2017; 11(6):459-469. doi:10.3855/jidc.8257

(Received 15 February 2016 – Accepted 02 January 2017)

Copyright © 2017 Khaleque et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Urinary tract infections (UTIs) are one of the most common human infections. The development of UTIs depends on the anatomy of the tract, the integrity of the host’s immunity, and the etiology of the infection [1]. UTIs are classified according to the site of infection: cystitis (the bladder), bacteriuria (the urine), or pyelonephritis (the kidneys) [2]. Successful establishment of infection by bacterial pathogens requires adhesion to host cells, colonization of tissues, and, in certain cases, cellular invasion followed by intracellular multiplication, dissemination to other tissues, or persistence [3]. A number of physiological factors such as sex, pregnancy, and diabetes can delineate the frequency, prevalence, and severity of UTIs [4].

Enteric bacteria are most commonly found as the etiologic agents of UTIs, with *E. coli* accounting for about 80% of UTI cases. Other pathogens associated with UTI include *Klebsiella* ssp., *Enterobacter* ssp., *Proteus* ssp., *Pseudomonas* ssp., *Staphylococcus saprophyticus*, and *Enterococcus* ssp. [5].

*Escherichia coli* is a remarkably diverse organism. A group of virulotypes have been implicated in a wide range of human and animal diseases, from gastroenteritis to extraintestinal infections of the urinary tract, bloodstream, and central nervous system [6]. Each of the virulotypes is distinct with respect to the subset of genes harbored that are involved in the subversion of host responses and pathogenic modulation. More than eight pathovars have been extensively studied, which are broadly classified as either diarrheagenic *E. coli* or extraintestinal *E. coli* (ExPEC). Six pathovars, which include enterohemorrhagic *E. coli* (EHEC), enteropathogenic *E. coli* (EPEC), enterotoxigenic *E. coli* (ETEC), enteroaggregative *E. coli* (EAEC), enteroinvasive *E. coli* (EIEC; including *Shigella* like species), and diffusely adherent *E. coli* (DAEC) are diarrheagenic, and two pathovars, which include uropathogenic *E. coli*...
(UPEC) and neonatal meningitis E. coli (NMEC) are the most common ExPEC isolates. UTI-causing E. coli isolates are broadly grouped in the ExPEC group and are commonly termed uropathogenic E. coli (UPEC) [7].

UPEC are well adapted to the challenge of moving from the intestinal tract to the urinary tract to establish themselves [8]. The ability to ascend the urinary tract reflects organ tropism defined by specific adhesins, evasion from innate immunity, and avoidance of clearance by urine flow [9]. Virulence factors of UPEC implicated in UTIs can be divided into two groups: the virulence factors associated with the bacterial surface (e.g., type 1 fimbriae, P fimbriae, S fimbriae, and afimbrial adhesins), and those factors which are secreted and exported to the site of action [10]. Secreted toxins are important virulence factors in a variety of E. coli-mediated diseases; for uropathogenic E. coli, a lipoprotein called α-hemolysin associated with upper UTIs [11] and cytotoxic necrotizing factor 1 (CNF1) involved in kidney invasion are noteworthy [12]. Secreted autotransporter toxin [13] and the cytolethal distending toxins (CDT) could also be potential virulence factors in UPECs [14].

In this study, we examined a collection of UPEC strains for the presence of characteristic virulence properties of UPEC and determined whether these UPEC strains carry virulence factors characteristic of diarrheagenic E. coli (DEC) pathotypes.

**Methodology**

**Sample collection**

Mid-stream urine samples were collected from UTI-suspected patients who attended a private hospital in Dhaka. Samples were collected from both outpatients and inpatients. Patients who were hospitalized for less than 24 hours were considered to be outpatients, and patients who were admitted to the hospital and stayed overnight or for a certain period of time, usually several days or weeks, were considered to be inpatients. Information forms with patients’ data (e.g., age, sex, clinical history, and pre-hospitalization medication) were recorded and duly supplied to the microbiology laboratory of the concerned hospital. The physical appearance and microscopic observations of urine samples are recorded in Table 1. Approximately 10 μL of each freshly voided midstream urine samples was streaked by semi-quantitative streaking method onto UTI chrome agar (HiMedia, Mumbai, India). Bacterial count was measured after overnight incubation at 37°C. Bacterial colony characteristics were observed and preliminarily identified by comparing data from the manufacturer of chrome agar media. A total of 71 pure isolates from UTI chrome agar were collected from the hospital and processed for identification and further biochemical analysis.

**Identification of isolates**

On the basis of colony morphology using differential and selective media, MacConkey agar No.3 (MAC-3) and eosin methylene blue agar (EMB) (Oxoid, Basingstoke, UK), presumptively identified E. coli colonies were further processed for biochemical tests [15] (synthesis of oxidase, catalase and urease, motility test, utilization of citrate, fermentation of glucose and lactose, production of indole) for the identification of the isolates.

**Observation of hemolytic activity**

Pure discrete colonies from nutrient agar (Oxoid, Basingstoke, UK) plates were streaked onto sheep blood agar (blood agar base, Oxoid, Basingstoke, UK) supplemented with 5% sheep blood and incubated overnight at 37°C. Zones of hemolysis were observed against bright light; indication of β-hemolysis was determined by the presence of zone of complete lysis of erythrocyte around the colony and clearing of media [16].

**Quantitative biofilm assay**

Quantitative biofilm assay was measured with a slight modification of the method described by Naves et al. [17]. Overnight bacterial culture in Luria-Bertani (LB) broth (Oxoid, Basingstoke, UK) was centrifuged, washed, and re-suspended in autoclaved distilled water that had an optical density of approximately 0.6 at 655 nm. A 96-well round-bottom polystyrene microtiter plate was inoculated with 200 μL of the bacterial suspension in each well, in triplicate. The microtiter plate was incubated at 28°C for 30 minutes, 2 hours, 8 hours, 24 hours, 48 hours, and 72 hours without shaking and then washed with the autoclaved water. The plate was stained with 200 μL of 0.5% crystal violet (Oxoid, Basingstoke, UK) in each well and incubated for 30 minutes, followed by washing. The absorbance was read after the addition of 200 μL of 95% ethanol in each well by an enzyme-linked immunosorbent assay (ELISA) plate reader at 450 nm (Bio-Rad, Hercules, USA). The optical density of each strain was obtained by arithmetic mean of three wells, and this value was then compared with mean absorbance of negative control.
Table 1. Virulence properties of all biochemically positive E. coli isolates.

| Isolate code | Age | Sex | Ip/Op | Pus cell (40 x) | RBC (40 x) | Yeast (40 x) | Biofilm formation capability | Hemolytic activity | UTI-associated E. coli virotypes | Diarrheagenic E. coli virotypes |
|--------------|-----|-----|-------|-----------------|-----------|-------------|------------------------------|-------------------|--------------------------------|--------------------------------|
| DUM 3383605  | 61  | M   | OP    | NUM            | 6-8       | -           | -               | γ                 | +     | afa   | -     | - | - | - | - | - | - | - | - |
| DUM 493783   | 82  | F   | IP    | 8-10          | 2-3       | -           | -               | γ                 | +     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 6397244  | 51  | F   | OP    | 6-8           | 1-3       | -           | Weak            | γ                 | -     | -     | +     | - | - | - | - | - | - | - | - |
| DUM 8E178254 | 93  | F   | IP    | NUM            | 2-3      | -           | -               | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 1539427  | 8   | M   | OP    | 1-3           | 6-8       | -           | -               | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 18397898 | 65  | F   | OP    | 4-6           | 0-2       | -           | -               | β                 | +     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 19343159 | 56  | F   | IP    | NUM            | 2-3      | ++          | -               | β                 | +     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 20396462 | 17  | F   | IP    | NUM            | 8-10     | -           | -               | γ                 | +     | +     | -     | - | - | - | - | - | - | - | - |
| DUM 21396669 | 59  | F   | OP    | NUM            | 2-3      | -           | -               | γ                 | -     | +     | -     | - | - | - | - | - | - | - | - |
| DUM 2222903  | 62  | F   | OP    | 4-6           | 1-2       | -           | -               | β                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 23398445 | 39  | F   | OP    | NUM            | 6-8      | -           | -               | γ                 | -     | -     | +     | - | - | - | - | - | - | - | - |
| DUM 26286615 | 75  | M   | IP    | 2-3           | 2-4       | -           | Weak            | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 28344871 | 1   | M   | OP    | 1-3           | OCC       | -           | -               | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 29361422 | 51  | F   | OP    | NUM            | 4-6      | -           | Medium          | γ                 | +     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 30224082 | 37  | F   | OP    | NUM            | 5-7      | -           | -               | γ                 | -     | -     | +     | - | - | - | - | - | - | - | - |
| DUM 32291185 | 62  | F   | OP    | 2-3           | 6-8       | -           | -               | β                 | +     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 33399573 | 27  | F   | OP    | NUM            | 2-3      | -           | -               | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 34355388 | 1   | F   | OP    | 6-8           | OCC       | -           | -               | γ                 | -     | +     | -     | - | - | - | - | - | - | - | - |
| DUM 36284390 | 30  | M   | OP    | NUM            | 2-4      | -           | Week            | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 38E383097 | 10 mo | F | OP    | 2-3           | NIL       | -           | -               | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 41357478 | 66  | M   | OP    | NUM            | 2-4      | -           | Weak            | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 43400330 | 40  | F   | IP    | NUM            | 8-10     | ++          | Weak            | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 44400401 | 55  | F   | OP    | NUM            | 1-2      | -           | Strong          | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 45400477 | 60  | F   | IP    | NUM            | 4-6      | -           | Medium          | γ                 | +     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 46408627 | 65  | F   | IP    | NUM            | 10-12    | -           | -               | γ                 | -     | -     | +     | - | - | - | - | - | - | - | - |
| DUM 47149386 | 25  | M   | IP    | 3-5           | 1-3       | -           | -               | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 48400795 | 40  | M   | OP    | NUM            | 10-12    | -           | Weak            | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 49396244 | 90  | M   | IP    | 6-8           | 5-7       | -           | Weak            | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 50390198 | 69  | F   | OP    | NUM            | 1-3      | -           | Weak            | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 51381966 | 25  | F   | OP    | NUM            | 2-3      | -           | Medium          | γ                 | -     | -     | +     | - | - | - | - | - | - | - | - |
| DUM 5438061  | 61  | F   | OP    | NUM            | 2-4      | -           | Medium          | γ                 | +     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 56401124 | 60  | F   | OP    | 8-10          | 1-2       | -           | Strong          | γ                 | -     | -     | -     | - | - | - | - | - | - | - | - |
| DUM 60401383 | 29  | F   | IP    | NUM            | -        | Weak         | -               | γ                 | +     | -     | -     | - | - | - | - | - | - | - | - |
Table 1 (continued). Virulence properties of all biochemically positive *E. coli* isolates.

| Isolate code | Age | Sex | Ip/Op | Pus cell (40 x) | RBC (40 x) | Yeast (40 x) | Biofilm formation capability | Hemolytic activity | UTI-associated *E. coli* virotypes | Diarrheagenic *E. coli* virotypes |
|--------------|-----|-----|-------|-----------------|-----------|-------------|-----------------------------|-------------------|---------------------------------|-------------------------------|
|              |     |     |       |                 |           |             |                             |                   | papC | afa | sfa | fim 1 | vrl | vt2 | eaeA | ial | estA | eltB | bfpA | aatA |
| DUM 6172747  | 48  | F   | IP    | NUM            | 1-3       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 62382265 | 26  | M   | OP    | NUM            | 8-10      | -           | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 63236990 | 46  | F   | IP    | NUM            | 6-8       | OCC         | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 65408845 | 42  | F   | IP    | NUM            | 1-2       | Week        | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 66205238 | 51  | F   | OP    | NUM            | 2-3       | -           | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 68401996 | 23  | F   | OP    | NUM            | -         | -           | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 70402007 | 45  | F   | IP    | NUM            | 6-8       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 71175237 | 6   | M   | OP    | 2-3            | 4-6       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 72309768 | 37  | F   | OP    | NUM            | 2-4       | Week        | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 73399414 | 74  | F   | OP    | 5-7            | 1-3       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 74402268 | 71  | F   | OP    | NUM            | 6-8       | Weak        | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 75401960 | 43  | F   | IP    | 2-4            | NUM       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 7622821  | 72  | F   | OP    | NUM            | 6-8       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 78376065 | 43  | M   | OP    | NUM            | 10-12     | Medium      | -              | β                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 80398564 | 61  | F   | OP    | 1-3            | NUM       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 81360474 | 82  | F   | IP    | 2-3            | 8-10      | +++         | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 82400477 | 60  | F   | OP    | NUM            | 8-10      | -           | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 84265373 | 104 | M   | IP    | NUM            | 1-2       | Weak        | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 85351596 | 52  | M   | OP    | 8-10           | 0-2       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 86402588 | 13  | F   | IP    | 10-12          | NUM       | +           | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 87387931 | 79  | F   | OP    | NUM            | 1-2       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 88307455 | 31  | F   | OP    | NUM            | 1-2       | -           | -              | γ                 | -    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |
| DUM 90243405 | 79  | M   | IP    | 4-6            | 8-10      | Weak        | -              | γ                 | +    | -   | -   | -     | -   | -   | -    | -   | -    | -    | -    |

| Total        | 56  |     |       |     |     |     |                             |                   | 21   | 5   | 24  | 6   | 0  | 15 | 0   | 1   | 2   | 1   | 1   |

UTI: urinary tract infection; M: male; F: female; IP: inpatients; OP: outpatients; NUM: too numerous to count.
The interpretation of biofilm formation assay was measured based on the formula BF = AB – CW, where BF is biofilm formation, AB is stained attached bacteria, and CW is stained control wells. The following classification was used for the determination of biofilm formation: no biofilm production when BF < 0.100; weak biofilm production when 0.100 ≤ BF ≤ 0.199; moderate biofilm production when 0.2 ≤ BF ≤ 0.299; and strong biofilm production when BF ≥ 0.300 [17].

**Molecular characterization of E. coli**

For extraction of DNA, the strains were grown on 6.0 mL of LB broth. After overnight growth, cells were harvested from the broth and subjected to alkaline cell lysis followed by the phenol-chloroform extraction method [18]. The DNA was stored at -20°C for subsequent polymerase chain reaction (PCR) analysis.

Genes of fim1 (type 1 fimbriae), papC (P fimbriae), afa (afimbrial adhesins), and sfa (S fimbriae) are known to be important determinants of pathogenesis for UPEC to establish initial adhesion for infection in the urinary tract. The bacterial isolates were screened for the presence of these genes by multiplex PCR; the sequence of oligonucleotide primers and PCR conditions are listed in Table 2. Detection of virulence marker genes associated with diarrheagenic *E. coli* was performed by multiplex PCR using eight primer pairs (Table 3) targeting genes eaeA (intimin of EHEC and EPEC strains), bfpA (bundle-forming pilus of EPEC strains), vt1 and/or vt2 (Shiga toxins 1 and 2 of EHEC strains), eltB and/or estA (enterotoxins of ETEC strains), iai (invasion-associated locus in EIEC and Shigella), and aatA (EcoRI-PstI DNA fragment of pCVD432 of EAE). The multiplex PCR reaction was segregated into three different sets, choosing primer pairs generating PCR products of different sizes distinguishable by agarose gel electrophoresis. A list of the oligonucleotide primers used in the assay is included in Table 3. PCR was performed in a 20 µL reaction mixture containing 1 µL of template DNA, 0.2 µL of 2 U/µL DNA polymerase (DyNAzyme, Thermo-Fisher Scientific, Waltham, USA.), 2 µL of 10× buffer for DyNAzyme, 0.4 µL of a mixture of deoxynucleoside triphosphates (25 mM of each), and 0.5 µL of 25 µM solution of each primer (Sigma-Aldrich, Munich, Germany). The thermocycler conditions (Peltier Thermal Cycler, MJ Research, 20°C for 2 minutes) were used for the determination of oligonucleotide primers and PCR conditions are listed in Table 2.
Waltham, USA) were as follows: of 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute for 30 cycles, with an initial denaturation at 96°C for 4 minutes and a final 7-minute extension at 72°C. The details of positive controls for each gene used in the study are included in Supplementary Table 1-S.

Results

A total of 71 pure cultures representing 71 UTI patients were collected randomly from a hospital situated in Dhaka, Bangladesh, of which 26 were inpatients and 45 were outpatients. UTI was confirmed in these patients by positive urine culture with about $10^5$ cfu/mL. Most of the patients (66%) were female, indicating a higher occurrence of UTIs among females.

Among the 71 isolates, 56 isolates were identified as *E. coli* according to colony morphology on the differential and selective media and biochemical tests performed in this study. Of these 56 *E. coli* strains, 62.5% were obtained from outpatients and 37.5% were from inpatients.

Biofilm formation is a prominent test for screening colonization efficiency onto the epithelial surface of the urinary tract, which is also a driving factor for UPEC strains to get established in the urinary tract. Among the tested isolates, almost 38% (21/56) were found to be capable of biofilm formation (Figure 1). Of these, 14 isolates were found to be weak biofilm producers, 5 were moderate biofilm producers, and 2 were strong biofilm producers. In the test for hemolytic activity, a few (5/56) isolates showed zone of β-hemolysis around the colony.

Initial attachment, colonization, and development of UTIs is partially determined by the presence of adhesive molecules on the bacterial surface. Among the 56 *E. coli* isolates, 24 were found to harbor the *papC* gene, a common adhesive gene for P fimbriae of uropathogenic *E. coli* strains. These P fimbriae can recognize kidney glycosphingolipids carrying Gal α(1–4) Gal determinant on renal epithelia via adhesion [7]. The attachment of P fimbriae to this receptor leads to the release of ceramide that acts as an agonist of toll-like receptor 4 (TLR4), a receptor involved in activation of the immune cell response [19]. This, in turn, leads to the development of local inflammation and pain associated with UTIs [20]. Fimbrial adhesion gene *fim1* was found in 15 isolates and afimbrial adhesion gene, *afa*, was found in 6 of the isolates. No isolates were
found to carry the sfa adhesin gene (Figure 2). Whereas the papC gene was found more frequently in inpatients (57%) than in outpatients (34%), the genes afa and type 1 were found more frequently in outpatients (11.4% and 34%, respectively) than in inpatients (9.5% and 14.3%, respectively).

Multiplex PCR assay was performed targeting eight genes (estA, eltB, vt1, vt2, eaeA, bfpA, ial, and aatA) usually harbored by five different diarrheagenic virotypes (ETEC, EHEC, EPEC, EIEC, EAEC), to assess the diarrheagenic potential of the UPEC isolates. Only seven isolates were found to harbor these diarrheagenic genes (Table 1). Among these seven isolates, two isolates were found to carry the estA gene, of which one (DUM 74402268) was also positive for papC and fim1 genes. The estA and eltB genes are characteristic of ETEC, and papC is characteristic of UPEC. The findings suggest that the isolate DUM 74402268 is either a UPEC strain containing the properties of ETEC or an ETEC strain possessing the properties of the UPEC pathotype. One isolate (DUM 43400330) was found to be positive for the eltB gene, but negative for all the four uropathogenic genes; thus, DUM 43400330 containing the eltB gene could putatively be characterized as ETEC. One isolate, DUM 6397244, found to be positive for vt2 and characterized as EHEC, was also positive for the fim1 gene. Another isolate (DUM 30224082) positive for the ial gene and characterized as EIEC was found to carry the fim1 gene as well. The isolate DUM 88307455, found to be positive for the bfpA gene and characterized as EPEC, was negative for all the other genes. Isolate DUM 56401124, found to harbor the aatA gene but negative for all four genes involved in uropathogenesis, was characterized as EAEC (Figure 3). Two ETEC strains, one containing only the estA gene and the other containing only the eltB gene, were obtained from inpatients. The other five were found in outpatients.

**Discussion**

We identified and characterized the virulence and possible diarrheagenic potential of UPEC isolates obtained from patients who had UTIs. Among the 71 isolates collected from the patients, 56 (78%) were identified as E. coli. Though the patients’ samples were randomly selected, 47 (65.2%) were from female patients and the rest (24; 34.8%) were from male patients, a result consistent with previous studies showing that UTIs are more common in women than in men and that many women experience persistent infection [21,22]. Women have a shorter urethra than men, and the urethral opening is relatively close to the anus in women; these are the probable causes of fecal-perineal-urethral contamination and development of UTIs in women [23]. There is also a strong association between anatomical and functional alterations of bladder emptying and recurrent UTIs in postmenopausal women [24]. In this study, around 47% of women were 55 years of age or older; the average
age of menopause in women in Asia is around 48 years [25].

For establishment of UTIs, uroepithelial adherence is critical. Strains of uropathogenic *E. coli* possess an impressive repertoire of adhesion molecules that enable the bacteria to aggregate and adhere to the cellular surfaces of the urinary tract [26]. Among the UTI-specific virulence-associated genes detected in this study by sets of multiplex PCR assay, *papC*, considered to be the second common virulence factor of UPEC [27], was found in 42% of isolates. *E. coli* can cause ascending UTIs when it has the challenge of ascending from the intestinal tract to establish an infection in the bladder (cystitis) and can proceed from the bladder via the ureters to the kidneys to cause pyelonephritis with the possibility of causing irreversible kidney damage and death [28].

Descending UTIs occur when the bacteria cause infection in kidney via blood or lymph nodes [28]. Though pyelonephritis is generally a descending infection, the presence of P fimbriae plays an important role in the pathogenesis of ascending UTIs and pyelonephritis in humans [27]. Moreover, the samples from which these strains were collected were urine, so it was difficult to say whether these *papC*-positive strains were responsible for ascending or descending UTIs. It was not confirmed, therefore, whether the patients had infection in their kidneys. If the infection was descending, which means the bacteria entered the bladder from blood via infecting kidney, this would suggest that the patients were already suffering from pyelonephritis. But if the bacteria ascended from the intestinal tract to lower urinary tract (the bladder) [2] via fecal-perineal-urethral route and caused infection there, that means the patients had not yet developed upper UTIs, but were at risk of developing upper UTI or pyelonephritis, as the bacteria possess the *papC* gene. It is more appropriate, therefore, to infer that these *papC*-positive strains have the ability to cause infection in the upper urinary tract (the kidneys) [2].

Martinez et al. [29] and Schembri et al. [30] showed that in murine UTI models, the type 1 fimbriae promote bacterial survival to stimulate mucosal inflammation and to enhance invasion and grow as a biofilm [29,30]. The type 1 fimbriae bind to the mannosylated glycoproteins uroplakin Ia and IIIa (UPIIIa) in the urothelial layer via the adhesin subunit FimH, which is located at the fimbral tip. The interaction results in molecular phosphorylation events that are required for stimulation of signaling pathways involved in invasion and apoptosis. These may also contribute to the elevation of intracellular Ca2+ levels in urothelial cells [29]. In clinical and experimental findings, it has been suggested that *E. coli* strains carrying *afa* adhesins are involved in UTIs and have properties potentially supporting the establishment of chronic or recurrent infection [31]. In this study, the gene *afa* was found in 6 (11%) and *fim*1 was found in 15 (27%) isolates. Though hemolysin is an effective toxin for UPEC and is usually associated with pyelonephritis [11], the occurrence of hemolytic activity was found to be limited in this study to only 5 (9%) isolates showing beta hemolysis on blood agar plate. Of these 5 isolates tested for the presence of the selected virulence genes, 2 carried both the *papC* and *fim*1 gene, 2 possessed only the *papC* gene, and 1 isolate was negative for all the other virulence genes examined in the study. Jakobsson et al. [32] reported permanent renal scarring as a common complication following hemolytic *E. coli* infection [32], which may be independent of bacterial adherence properties [33]. In this study, we observed that among the 5 strains showing beta-hemolytic activity, 4 showed no evidence of biofilm formation in vitro assays (Table 1).

Melican et al. [34] defined previously unknown synergistic functions of both P fimbriae and type 1 fimbriae that facilitate bacterial colonization under dynamic *in vivo* conditions. P fimbriae have been shown to enhance early colonization of the tubular epithelium, while the type 1 fimbriae mediate colonization of the center of the tubule via a mechanism that involves inter-bacterial binding and biofilm formation. The heterogeneous bacterial community within the tubule subsequently affects renal filtration, leading to total obstruction of the nephron. The obstruction contributes to the full pathophysiology of pyelonephritis [34]. In our study, 10 isolates (18%) were found to be positive for both *fim*1 (gene for type 1 fimbriae) and *papC* (a gene of P fimbriae). Formation of biofilm protects bacteria from hydrodynamic wash in the urinary tract, from phagocytosis and other host defense mechanisms, and from antibiotic chemotherapy [35], which contributes to the persistence of bacteria. Several isolates (21/56) in this study were found to be capable of biofilm formation. Thirteen of the isolates that exhibited biofilm formation ability also possessed at least one of the four uropathogenic adhesin genes. Among the thirteen isolates, seven were found to carry the *papC* gene alone, three were found to harbor both *papC* and *fim*1, and one was positive for *papC* and *afa* genes. One isolate was positive for the *afa* gene alone and one was carrying *fim*1 alone; the remaining eight isolates were carrying none of these uropathogenic adhesin genes, or there may have been some other...
mechanism by which they were able to form the biofilm that results in infection in the urinary tract. In addition, Pruss et al. [36] showed that the expression of hemolysin and type 1 fimbriae was significantly associated with biofilm production. Type 1 fimbriae, which enhance adhesion to host epithelial cells, have been found to be important in the initial steps of biofilm formation [36]. In our study, the fimI gene (type 1 fimbriae) was found only in six biofilm-forming strains, and only one strain was found to be positive for both hemolytic activity and biofilm formation.

Other virulence-associated genes, more frequently found in diarrheagenic pathotypes, were detected in only seven isolates by three sets of multiplex PCR using eight different primer pairs targeting vt1, vt2, ial, eaeA, astA, estA, eltB, and bfpA genes. More than 85% of the UPEC strains carried none of these eight diarrheagenic-associated genes, although there is little information on the role of these genes in uropathogenesis. This study shows evidence that diarrheagenic and uropathogenic strains may share common virulence properties. The isolates we examined may have the capacity of causing both intestinal and extraintestinal infection. Three isolates were detected as having the properties of ETEC, among which one also carried two important uropathogenic genes, papC and fimI (Table 1). Though the product of the estA gene has no role in urinary tract infections, the presence of these three significant genes (papC, fimI, and estA) in a single isolate indicate its potential capability to cause infection in both the intestinal and urinary tracts. The eltB gene possessing the ETEC strain, the astA gene containing the EAEC strain, and the vt2 gene-positive EHEC strain, though negative for all other uropathogenic genes, were capable of biofilm formation, which may explain their ability to colonize the urinary tract, leading to infection. Another two E. coli strains (DUM 88307455 and DUM 30224082) found to be carrying a diarrheagenic gene and negative for all other uropathogenic virulent properties (Table 1), made it necessary to find out how they developed into infection in the urinary tract. Again, the isolates found to harbor a diarrheagenic gene, whether they developed into ascending or descending UTIs, could not be deduced. As these strains were found to carry a diarrheagenic gene, the possibility of ascending UTI was higher in this respect. This study raises the possibility that some UPEC may have acquired DEC markers, becoming a potential cause of diarrhea, or that some diarrheal E. coli strains may have acquired properties of UPEC by means of horizontal gene transfer or some other mode, which requires further study. Though the percentages of in-and outpatients regarding the presence of particular virulence gene were enumerated, no significant relationship was observed between the patients’ hospital residency and the prevalence of virulence genes.

Our study had a few similarities and differences with other studies on UPEC. A study in Iran found that 9.4% of the 138 UPEC strains were carrying astA, a gene characteristic of the EAEC pathotype [37]. Abe et al. [38] found 16 UPEC strains (7.1%) positive for the astA gene sequence, a typical gene of the EAEC pathotype [38]. In Copenhagen, Denmark, a study on an UTI outbreak detected the presence of EAEC virulence genes in UPEC strains and demonstrated that in the presence of adhesin genes of EAEC, outbreak UTI strains exhibited increased adherence to human bladder epithelial cells compared to prototype UPEC strains [39]. In Germany, a study found that of 265 E. coli strains collected from urine samples, 28 (10.6%) were positive for one or more known diarrheagenic pathogenic E. coli virulence genes, and among these 28 isolates, 23 were found to carry the astA gene of EAEC [40]. In all these studies on E. coli strains isolated from urine samples of UTI patients, EAEC characteristic virulence genes were observed more than other diarrheal E. coli pathotypes. In our study, conducted in Bangladesh, we found that 12.5% of the UPEC strains possessed diarrheagenic genes of different pathotypes.

Twenty-five percent of the isolates were found to be negative for all the 12 genes assessed and also showed negative in hemolysis activity and biofilm formation assay. Interestingly, most of them were isolated from elderly patients, which supports the hypothesis that the commensal E. coli may also cause UTIs, especially in elderly patients who may have suppressed immunity, or that these strains possess some other virulence properties which were not included in this study.

Conclusions
A proportion of the isolates in this study were found to carry properties of both UPEC and DEC. These isolates have expanded their site of infection, gaining the ability to cause infection in both the intestinal and urinary tracts, and have thus become of great clinical importance in our setting.

References
1. Nicolle LE (2002) Urinary tract infection in geriatric and institutionalized patients. Curr Opin Urol 12: 51-55.
2. Foxman B (2003) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 49: 53-70.
3. Trautner BW, Hull RA, Darouiche RO (2003) *Escherichia coli* 83972 inhibits catheter adherence by a broad spectrum of uropathogens. Urology 61: 1059-1062.

4. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Hoekstra JB, Bouter KP, Bravenboer B, Collet JT, Jansz AR, Hoepelman AI (2000) Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care 23: 744-749.

5. Ronald A (2003) The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 49: 71-82.

6. Croxon MA, Finlay BB (2010) Molecular mechanisms of *Escherichia coli* pathogenicity. Nat Rev Microbiol 8: 26-38.

7. Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic *Escherichia coli*. Nat Rev Microbiol 2: 123-140.

8. Alteri CJ, Smith SN, Mobley HL (2009) Fitness of *Escherichia coli* during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog 5: e1000448.

9. Wiles TJ, Kulesus RR, Mulvey MA (2008) Origins and virulence mechanisms of uropathogenic *Escherichia coli*. Exp Mol Pathol 85: 111-119.

10. Emody L, Kerenyi M, Nagy G (2003) Virulence factors of uropathogenic *Escherichia coli*. Int J Antimicrob Agents 22 Suppl 2: 29-33.

11. Johnson JR (1991) Virulence factors in *Escherichia coli* urinary tract infection. Clin Microbiol Rev 4: 80-128.

12. De Rycke J, Milon A, Oswald E (1999) Nectrotic *Escherichia coli* (NTEC): two emerging categories of human and animal pathogens. Vet Res 30: 221-233.

13. Guyer DM, Rudulovic S, Jones FE, Mobley HL (2002) Sat, the secreted autotransporter toxin of uropathogenic *Escherichia coli*, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect Immun 70: 4539-4546.

14. Toth I, Herault F, Beutin L, Oswald E (2003) Production of cytolethal distending toxins by pathogenic *Escherichia coli* strains isolated from human and animal sources: establishment of the existence of a new cdt variant (Type IV). J Clin Microbiol 41: 4285-4291.

15. Cheesbrough M (2006) Microbiological Tests. District Laboratory Practice in Tropical Countries Part 2, 2nd Edition. Cambridge: Cambridge University Press. 124-145.

16. Siegfried L, Kmetova M, Janigova V, Sasinka M, Takacova V (1995) Serum response of *Escherichia coli* strains causing dyspepsia and urinary tract infection: relation to alpha-hemolysin production and O type. Infect Immun 63: 4543-4545.

17. Naves P, del Prado G, Huelves L, Gracia M, Ruiz V, Blanco J, Rodriguez-Cerrato V, Ponte MC, Soriano F (2008) Measurement of biofilm formation by clinical isolates of *Escherichia coli* is method-dependent. J Appl Microbiol 105: 585-590.

18. Chowdhury NR, Chakraborty S, Ramamurthy T, Nishibuchi M, Yamasaki S, Takeda Y, Nair GB (2000) Molecular evidence of clonal Vibrio parahaemolyticus pandemic strains. Emerg Infect Dis 6: 631-636.

19. Fischer H, Ellström P, Ekström K, Gustafsson L, Gustafsson M, Svanborg C (2007) Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4. Cell Microbiol 9: 1239-1251.

20. Bergsten G, Wullt B, Svanborg C (2005) *Escherichia coli*, fimbriae, bacterial persistence and host response induction in the human urinary tract. Int J Med Microbiol 295: 487-502.

21. Minardi D, d`Anzeo G, Cantoro D, Conti A, Muzzonioglu G (2011) Urinary tract infections in women: etiology and treatment options. Int J Gen Med 4: 333-343.

22. Hooton TM, Stapleton AE, Roberts PL, Winter C, Scholes D, Bavendam T, Stamm WE (1999) Perineal anatomy and urine-voiding characteristics of young women with and without recurrent urinary tract infections. Clin Infect Dis 29: 1600-1601.

23. Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, Yoshida O (1997) Genetic evidence supporting the feocal-perineal-urethral hypothesis in cystitis caused by *Escherichia coli*. J Urol 157: 1127-1129.

24. Raz R, Gennesy N, Wasser J, Stoler Z, Rosenfeld S, Rottenstreich E, Stamm WE (2000) Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 30: 152-156.

25. Kinga V (2000) Menopause and Treatments. Quality of Life Research 9 Suppl 1: 695-707.

26. Mulvey MA (2002) Adhesion and entry of uropathogenic *Escherichia coli*. Cell Microbiol 4: 257-271.

27. Vaisanen V, Elo J, Tallgren LG, Siitonen A, Makela PH, Svanborg-Edén C, Kallenius G, Svenson SB, Hultberg H, Korhonen T (1981) Mannose-resistant haemagglutination and P antigen recognition are characteristic of *Escherichia coli* causing primary pyelonephritis. Lancet 2: 1366-1369.

28. Salvatore S, Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, Torella M (2011) Urinary tract infections in women. Eur J Obstet Gynecol Reprod Biol 156: 131-136.

29. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren SJ (2000) Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 19: 2803-2812.

30. Schembri MA, Klemm P (2001) Biofilm formation in a hydrodynamic environment by novel fimh variants and ramifications for virulence. Infect Immun 69: 1322-1328.

31. Le Bouguenec C (2005) Adhesins and invasins of pathogenic *Escherichia coli*. Int J Med Microbiol 295: 471-478.

32. Jakobsson B, Berg U, Svensson L (1994) Renal scarring after acute pyelonephritis. Arch Dis Child 70: 111-115.

33. Mobley HL, Green DM, Triffilis AL, Johnson DE, Chippendale GR, Lockatell CV, Jones BD, Warren JW (1990) Pyelonephritic *Escherichia coli* and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun 58: 1281-1289.

34. Melican K, Sandoval RM, Kader A, Joseffson L, Tanner GA, Molitoris BA, Richter-Dahlfors A (2011) Uropathogenic *Escherichia coli* P and Type 1 fimbriae act in synergy in a living host to facilitate renal colonization leading to nephron obstruction. PLoS Pathog 7: e1001298.

35. Hanna A, Berg M, Stot V, Razatos A (2003) Role of capsular colanic acid in adhesion of uropathogenic *Escherichia coli*. Appl Environ Microbiol 69: 4474-4481.

36. Pruss BM, Besemann C, Denton A, Wolfe AJ (2006) A complex transcription network controls the early stages of biofilm development by *Escherichia coli*. J Bacteriol 188: 3731-3739.

37. Mirzarazi M, Rezatofighi SE, Pourmahdi M, Mohajeri MR (2015) Occurrence of genes encoding enterotoxins in uropathogenic *Escherichia coli* isolates. Braz J Microbiol 46: 155-159.

38. Abe CM, Salvador FA, Falsetti IN, Vieira MA, Blanco J, Blanco JE, Blanco M, Machado AM, Elias WP, Hernandes RT, Gomes TA (2008) Uropathogenic *Escherichia coli* (UPEC)
strains may carry virulence properties of diarrheagenic E. coli. FEMS Immunol Med Microbiol 52: 397-406.

39. Boll EJ, Struve C, Boisen N, Olesen B, Stahlhut SG, Krogfelt KA (2013) Role of enteroaggregative Escherichia coli virulence factors in uropathogenesis. Infect Immun 81: 1164-1171.

40. Toval F, Kohler CD, Vogel U, Wagenlehner F, Mellmann A, Fruth A, Schmidt MA, Karch H, Bielaszewska M, Dobrindt U (2014) Characterization of Escherichia coli isolates from hospital inpatients or outpatients with urinary tract infection. J Clin Microbiol 52: 407-418.

41. Johnson JR, Stell AL (2000) Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 181: 261-272.

42. Yamamoto S, Terai A, Yuri K, Kurazono H, Takeda Y, Yoshida O (1995) Detection of urovirulence factors in Escherichia coli by multiplex polymerase chain reaction. FEMS Immunol Med Microbiol 12: 85-90.

43. Moseley SL, Hardy JW, Hug MI, Echeverria P, Falkow S (1983) Isolation and nucleotide sequence determination of a gene encoding a heat-stable enterotoxin of Escherichia coli. Infect Immun 39: 1167-1174.

44. Inoue T, Tsuji T, Koto M, Imamura S, Miyama A (1993) Amino acid sequence of heat-labile enterotoxin from chicken enterotoxigenic Escherichia coli is identical to that of human strain H10407. FEMS Microbiol Lett 108: 157-161.

45. Yatsuyanagi J, Saito S, Miyajima Y, Amano K, Enomoto K (2002) Characterization of enteropathogenic and enterohaemaggregative Escherichia coli isolated from diarrheal outbreaks. J Clin Microbiol 40: 294-297.

46. Schmidt H, Knop C, Franke S, Aleksic S, Heesemann J, Karch H (1995) Development of PCR for screening of enterohaemaggregative Escherichia coli. J Clin Microbiol 33: 701-305.

47. Frankel G, Riley L, Giron JA, Valmassoi J, Friedmann A, Stockbne N, Falkow S, Schoolnik GK (1990) Detection of Shigella in feces using DNA amplification. J Infect Dis 161: 1252-1256.

48. Pollard DR, Johnson WM, Lior H, Tyler SD, Rozee KR (1990) Rapid and specific detection of verotoxin genes in Escherichia coli by the polymerase chain reaction. J Clin Microbiol 28: 540-545.

49. Lindqvist R (1997) Preparation of PCR samples from food by a rapid and simple centrifugation technique evaluated by detection of Escherichia coli O157:H7. Int J Food Microbiol 37: 73-82.

50. Svenungsson B, Lagergren A, Ekwall E, Evengard B, Hedlund KO, Karmell A, Lofdahl S, Svensson L, Weintraub A (2000) Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. Clin Infect Dis 30: 770-778.

Corresponding author
Anowara Begum, Ph.D.
Department: Department of Microbiology
Institution: University of Dhaka
Department of Microbiology
University of Dhaka
Post code: 1000
City: Dhaka
Country: Bangladesh
Phone: +8801926923962
Fax: +88 02 9667222
E-mail: anowara@du.ac.bd

Conflict of interests: No conflict of interests is declared.
Annex – Supplementary Items

Supplementary Table 1. Positive controls for pathogenic genes.

| No. | Isolate codes | Genes   | GenBank accession No. |
|-----|---------------|---------|-----------------------|
| P1  | mduc1Lvve     | vt1, vt2, eaeA | KY319038, KY221829, KY073237 |
| P2  | mduc5sB       | bfpA    | KY221831              |
| P3  | mduc7i        | iai     | KY221830              |
| P4  | mdueR1Pc      | aatA    | KY243935              |
| P5  | mduc1iLS      | estA, eltB, papC | KY221833, KY221832, KY243934 |
| P6  | mduc20PAT     | afa     | KY290889              |
| P7  | mdues7s       | fim1, sfa | KY319036, KY319037    |